Neuren Media and Analyst Coverage, page-1317

While time requirements to develop a drug are independent of who is undertaking the development, whether that development is able to be commenced is dependent on access to its required funding.

A critical difference between NEU and Big Pharma is the different levels of developmental funding accessible for this purpose.

NEU’s indicated approach has been to maximise shareholder value by concentrating on achieving regulatory approvals for as many developed indications it is able to fund, after assessing related risk and market size. That is what it is set up to do.

As correctly pointed out by @SouthernAccent and @phmurphy01 above, the next step in the process is drug commercialisation. This requires manufacturing and global marketing and sales infrastructure that, like most other small Australian biotechs, is impractical for NEU to consider establishing, necessitating the baton to be passed over to BP eventually. Preferably once a maximum amount of value has been created.